Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-541468 (Daridorexant) Respiratory Safety in Moderate COPD
NCT03646864Phase 1Completed
- Sponsor
- Idorsia
- Start
- Nov 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Insomnia comparing Daridorexant with Placebo (2 arms). Primary endpoint: Mean Oxygen Saturation during Total Sleep Time. Started Nov 2018; status: completed.
02
Drugs
daridorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03646864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646864.